Wells Pharmacy, Inc., Dyersburg, TN
Is Wells Pharmacy, Inc. registered with the FDA as a 503B outsourcing facility?
Record found. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Wells Pharmacy, Inc. in Dyersburg, TN, first registered Jun 7, 2016 and most recently registered Oct 14, 2026.
Does Wells Pharmacy, Inc. hold a Tennessee pharmacy license?
State pharmacy license records for Tennessee are not checked: the Department of Health’s license verification site did not respond to this index’s requests. This index reads only that state’s board actions.
Has Wells Pharmacy, Inc. had a state board action or FDA letter?
FDA letters: record found. FDA’s registered outsourcing facility list gives the action on its last inspection, Apr 9, 2026, as “Response Letter Issued 10/5/2026; FMD-145 Letter Issued 10/6/2026”. State board actions: no Tennessee Board of Pharmacy action under this exact name and city was found in the Board of Pharmacy sections of the Tennessee Department of Health’s monthly Disciplinary Action Reports (actions dated January 2004 to April 2026) on Nov 15, 2026.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Wells Pharmacy, Inc.
- Location
- Dyersburg, TN
- Type as FDA labels it
- 503B
- FDA 503B list
- Listed as Wells Pharmacy, Inc.
- Form 483s on FDA’s actions page
- 0
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- None listed
- FDA Data Dashboard inspections
- 4 inspections: 1 OAI, 3 VAI; 5 published Form 483s
- Form 483 text on this page
- 3 Form 483s, 16 observations
- State board records
- Not checked (license records); board actions matched: 0
FDA inspections and letters
No entry for this name and location was matched on FDA’s compounding inspections and actions page (current as of Oct 22, 2026). That page covers actions from 2019 on; FDA keeps earlier ones in its archive.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Wells Pharmacy, Inc, Dyersburg, TN (FEI number 3011761321), matched to this page by exact name, city and state. It lists 4 inspections: 1 OAI, 3 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Apr 25, 2025 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3011761321 | 1271216 |
| Jan 28, 2021 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3011761321 | 1135134 |
| Apr 27, 2018 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3011761321 | 1050115 |
| Oct 20, 2016 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3011761321 | 989731 |
Form 483s FDA has published for this site
- Apr 9, 2026: Form 483 to Wells Pharmacy, Inc, published May 8, 2026. fda.gov
- Apr 25, 2025: Form 483 to Wells Pharmacy, Inc, published Aug 7, 2025. fda.gov
- Jan 28, 2021: Form 483 to Wells Pharmacy, Inc, published Mar 31, 2021. fda.gov
- Oct 24, 2018: Form 483 to Wells Pharmacy, Inc, published Jan 17, 2024. fda.gov
- Apr 12, 2017: Form 483 to Wells Pharmacy, Inc, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 16 numbered observations in all, across 3 inspections ending Oct 20, 2016 to Apr 9, 2026. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Apr 6, 2026 to Apr 9, 2026: 2 observations
- Firm on the cover
- Wells Pharmacy, Inc, 450 Us Highway 51 Byp N, Dyersburg, TN 38024-3655
- FEI number
- 3011761321
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 404 BNA Dr., Bldg. 200, Ste. 500 Nashville, TN 37217-2597
- Matched to this page by
- FEI number on the cover; linked from actions page, 503B list, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
Specifically,
A) Inadequate Cleaning Validation
Your cleaning validation (Disinfectant Efficacy Study) does not evaluate whether your cunent cleaning agents and procedures effectively remove hazardous drug products to prevent cross -contamination or product carryover
. The cleaning agent manufacturer study provided as evidence for hazardous drug removal is inadequate for the following reasons: Your firms pellet press and metal detector are used during the manufacturing process of all hazardous drug products such as Testosterone, Estradiol, and Progesterone. For example, your firm used the <Redacted B4> Tablet Press and <Redacted B4> Metal Detector during the production of Testosterone 50mg Cholesterol, Lot 02242026TN2, expiration date 02/11/2027 and Estradiol 6mg, Lot 11202025TN2 expiration date 11/20/2026. Both sterile finished drug products were approved and released for distribution. ...
Observation 2
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.
Specifically,
Your firm has failed to establish hardness specifications to demonstrate that these drug products conform to appropriate quality standards. Your hardness analyses demonstrate wide ranges of intra-batch results. For example, such variability was observed in the following lots:
Drug Product Lot Hardness Test Results Low (kgF)
Hardness Test Results High (kgF'
Qty Made
Qty Distributed
Testosterone 50mg Cholesterol
02242026TN2 4.4
<Redacted B4> Testosterone/ Anastrozole 10014mg
08262025TN2 5.4
Estradiol 10mg
10212025TN3 8.3
Testosterone 100mg SA
01232026TN4 4.7
Testosterone 200mg SA
01222026TN3
Progesterone 100mg
04262024TN2 1.02
Testosterone 200mg SA
03272024TN3 4.76
Progesterone 100mg, Lot 04262024TN2, expiration date, received a complaint of 7 broken pellets in one order. Testosterone 200mg SA, lot 03272024TN3, expiration date, received a complaint of 3 pellets crumbling to dust when handling. ...
Inspection Dec 1, 2020 to Jan 28, 2021: 8 observations
- Firm on the cover
- Wells Pharmacy, Inc, 450 Us Highway 51 Byp N, Dyersburg, TN 38024-3655
- FEI number
- 3011761321
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 404 BNA Dr., Bldg. 200, Ste. 500 Nashville, TN 37217-2597
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Specifically,
A.
Testosterone 100mg (Lot# 03182020TN) <Redacted B4> Implantable hormonal pellets intended to be sterile, failed sterility testing for Chaetomium globosum (fungus) after <Redacted B4> sterilization from your third-party contract testing laboratory. Your quality unit noted an 81 % recovery of Chaetomium globosum over the last 30 months, with an increasing frequency over the last 12 months . In addition, a third-party janitorial company concluded, "the HVAC system inclucling the <Redacted B4> the air returns, walls, ceilings, and floors of the suite were all contaminated with mold." Your firm's quality unit failed to conduct a thorough investigation to address the source of this contamination. For example, but not limited to, your firm's Vice President of Quality Assurance stated on 09/02'2020, a third-party contractor performed cleanings to eradicate your firm's fungus/mold concerns. However, Chaetomium globosum was recovered at your facility on 10/07/2020. ...
Observation 2
Buildings used in the manufacture, processing, packing, or holding of a drug product do not have the suitable construction to facilitate cleaning, maintenance, and proper operations.
***THIS IS A REPEAT OBSERVATION FROM FDA 483 issued in 2018 (Observation 7)* * *
Specifically, your firm has structural and equipment deficiencies in the classified areas which do not ensure clean airflow, including, but are not limited to:
A. In your firm's ISO 7-1 package room and ISO 7-2 pellet room where implantable hormonal pellets intended to be sterile are produced, we observed the following:
a. Gaps around the perimeter of your firm's ceiling HEPA filter screens and
b. Excess caulking located on the ceiling that is not smooth and not easily cleanable.
B. In your firm's ISO 7-1 package room, the light fixtures are not smooth and are not easily cleanable.
C. Your firm's <Redacted B4> Preventative Maintenance Report, dated 11/18/2020, performed by a third-party contractor, documents your facility has <Redacted B4> , that have excessive rust damage. ...
Observation 3
Equipment and utensils are not maintained at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.
Specifically, on 12/01/2020, we observed obvious surface abrasions located on the faceplate of your firm's pellet press, EQ00l , that come in direct contact with drug components during processing for implantable hormonal pellets intended to be sterile. Your firm's Vice President of Quality Assurance explained production operators would note equipment damages on your firm's batch record. However, your firm's written procedures for batch records do not address the documentation of equipment concerns. In addition, your firm's batch records do not have an allocated space for equipment concerns. Furthermore, your firm's written procedures for the preventative maintenance of the pellet press do not address the visual inspection of the pellet press for damages prior to production.
Your firm produced ancl released at least <Redacted B4> lots ( approximately <Redacted B4> implantable sterile hormonal pellets) on EQ00l that are within expiry.
Please refer to OBSERVATION 4 for additional Quality Unit concerns.
Observation 4
The quality control unit lacks responsibility to approve and reject all procedures or specifications impacting on the identity, strength, quality and purity of drug products.
***THIS IS A REPEAT OBSERVATION FROM FDA 483 issued in 2018 (Observation 2)***
Specifically, during an intetview with your firm's Quality Assurance Supervisor, who is onsite daily, is responsible for, but not limited to: review and release of your firm's batch records; routine monitoring reviews; and oversees your firm's environmental monitoring program, stated they do not make quality decisions due to lack of experience or authority. For example, but not limited to:
A. On 12/07/2020, your firm's Quality Assurance Supervisor stated they acknowledged the gaps in your firm's ISO 7-2 Packaging Room and ISO 7-1 Pellet Room ceilings and stated these gaps may cause disruption in the quality of air. However, the Quality Assurance Supervisor does not review your firm's cleanroom certification reports and explained this review was conducted by the Quality Unit located in Ocala, Florida. ...
Observation 5
Complaint records are deficient in that they do not include the findings of the investigation and follow-up.
Specifically,
A. Your firm received a complaint involving hospitalization and sepsis after a patient received Estradiol 6mg (Lot #05282019TN <Redacted B4> Testosterone 37.5mg (Lot #04012019TN <Redacted B4> and Testosterone 100mg (Lot #04222019TN <Redacted B4> our quality unit failed to conduct an investigation for this complaint. In addition, your 2019 Micro ID log report, provided by your firm's Vice President of Quality Assurance, documents your pellet production employees recovered Staphylococcus epidermis and Paenibacillus provencensis during fingertip samplings on 04/22/2019 and 05/28/2019, respectively. In addition, samples for personnel monitoring and environmental monitodng were taken at your facility on 04/22/2019 and 05/28/2019. The following microbiological organisms were identified:
Sample Date
ID
CFU
Staphylococcus epidermidis
Micrococcus luteus
Staphylococcus epidermidis
Dietzia cinnamea
Staphylococcus hominis
Micrococcus luteus
Paenibacillus provencensis
Paenibacillus lautus
Coryneform bacillus
Paenibacillus glucanolyticus
Bacillus horneckiae ...
Observation 6
Individuals responsible for supervising the manufacture, processing, packing and holding of a drug product lack the training to perform their assigned functions in such a manner as to assure the drug product has the safety, identity, strength, quality and purity that it purports or is represented to possess.
Specifically, your SOP 9.300: Training Program, states GMP training shall be conducted for each employee <Redacted B4> based on date of previous GMP training. However, there are no assurances the following employees have completed your firm's <Redacted B4> and refresher CGMP training requirements.
Daily Duties and Responsibilities include but not. limited to:
Title
Date of Hire
Vice President of Quality Assurance
Ensures compliance with US FDCA, Section(s) 503A & 503B and all its related elements such as facilities, documentation, training, reports, and records (e.g. final review of all procedures, oversees all quality assurance, quality control, and regulatory duties). Please refer to OBSERVATIONS 1, 2, 3, 4, 5, 8 for quality concerns
Vice President of Operations
Oversees daily operations of Ocala, FL and Dyersburg, TN facilities (e.g. ...
Observation 7
You compound drugs that are essentially a copy of one or more approved drugs within the meaning of sections 503B(a)(5) and 503B(d)(2).
Specifically, your firm compound drug products that:
(a) are identical or nearly identical to an approved drug that is not on the drug shortage list in effect under section 506E at the time of compounding, distribution, and dispensing; or
(b) are not identical or nearly identical to an approved drug but contain a bulk drug substance that is also a component of an approved drug, and for which there is no change that produces for an individual patient a clinical difference, as determined by the prescribing practitioner, between the compounded drug and the comparable approved drug.
Examples of compounded drug products that are essentially a copy of one or more approved drugs include:
• Testosterone 12.5 mg Pellets
• Testosterone 37.5 mg Pellets
• Testosterone 50 mg Pellets
• Testosterone 62.5 mg Pellets
• Testosterone 87.5 mg Pellets
• Testosterone 100 mg Pellets
• Progesterone 50 mg Pellets
• Progesterone 100 mg Pellets
Observation 8
Your outsourcing facility has not submitted an adverse event report to FDA in accordance with the content and format requirements established through guidance or regulation under 21 CFR 310.305 as required by section SOJB(b)(S).
Specifically, on 07/15/2019, your firm received an Adverse Event, ADR-TN 2019-001, for Estradiol 6 mg, Testosterone 37.5 mg, and Testosterone 100 mg pellets, for a patient that was hospitalized and tested positive for sepsis. However, this was not reported to FDA until 02/21/2020.
The Adverse Event Report was not reported to FDA within 15 calendar days after first receiving information about the adverse event.
Please refer to OBSERVATION 5 for additional details.
Inspection Sep 12, 2016 to Oct 20, 2016: 6 observations
- Firm on the cover
- 450 US Highway 51 BYPN Wells Pharmacy Network, LLC, CODE
- FEI number
- 3011761321
- Establishment type on the cover
- Producer of Sterile Products Dyersburg, TN 38024 THIS DOCUMENT LISTS OBSERVATIONS MADE BY THE FDA REPRESENTAlIVE(S) DURING THE INSPECTION OF YOUR FACILITY. THEY ARE INSPECTIONAL OOSERVATIONS; AND DO NOT REPRESENT A FINAL AGENCY DETERMINATION REGARDING YOUR COMPLIANCE. IF YOU HAVE AN OBJECTION REGARDING AN OBSERVATION, OR HAVE IMPLEMENTED, OR PLAN TO IMPLEMENT CORRECTIVE ACTION IN RESPONSE TO AN OBSERVATION, YOU MAY DISCUSS THE OBJECTION OR ACTION WITH THE FDA REPRRESENTATIVE(S) DURING THE INSPECTION OR SUBMIT THIS II'FORMATION TO FDA AT THE ADDRESS ABOVE. IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT FDA AT THE PHONE NUMBER AND ADDRESS ABOVE. DURING INSPECTION OF YOUR FIRM WE OBSERVED
- FDA district office on the cover
- New Orleans District Office 404 BNA Drive, Bldg 200, Suite 500 Nashville, TN 37212 61 5-366-7801 Industry Information: www.fda.gov/oc/industry
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Buildings used in the processing of a drug products are not maintained in a good state of repair.
Specifically,
1. Multiple gaps were observed around the light fixture in the ISO 5 room. 2. Water damage was observed in the ceiling of the unclassified area adjacent to the clean room area. In addilion, the unclassified area shares a wall with the clean room and multiple gaps were observed in the ceiling tiles directly above this shared wall.
Observation 2
Non-depyrogenated containers were used in drug production. Your drug product containers were not processed to remove pyrogenic properties to assure that they are suitable for their intended use.
Specifically, the blister packaging used by the firm is not purchased as pyrogen-free and your firm does not depyrogenate this container closure prior to use.
Observation 3
The flow of drug products through the building is not designed to prevent contamination.
Specifically, there is a potential risk for contamination during the compounding of bulk powdered drugs.
1. Non-dedicated equipment such as the <Redacted b4> tablet press, and <Redacted b4> used in the production ofyour firm's implantable hormonal pellets is not adequately cleaned between each batch to prevent cross-contamination.
3. The <Redacted b4> used in your firm's <Redacted b4> and <Redacted b4> does not meet the manufactures specifications, which has a potential for cross-contamination when mixing your bulk powdered drugs.
Observation 4
The use of the sporicidal agent in the cleanrooms is inadequate.
Specifically, Written procedures are not followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product. Your firm fails to use a sporicidal agent in the ISO 5 area on a frequent basis. <Redacted b4> is not an effective sporicidal agent when a <Redacted b4> is used.
Observation 5
Procedures designed to prevent microbiological contamination of drug products are not established, written, and followed.
Specifically, your firm's written procedures, SOP 3.110-Environmental Monitoring Dyersburg, TN, states in section 8.5, <Redacted b4> The media fills associated with <Redacted b4> qualification for sterile product compounding personnel are inadequate. Some deficiencies include but are not limited to:
1. The firm failed to conduct appropriate follow-up investigations and provide documentation identifying the organisms or species for each colony growth for the following <Redacted b4> plate (Action limit <Redacted b4>
09/09/2016: <Redacted b4> 09/07/2016: <Redacted b4>
Observation 6
Your firm failed to conduct smoke studies under dynamic conditions.
Specifically, the most recent qualification of the <Redacted b4> areas completed on <Redacted b4> by a outside
Linked 483s whose text is not shown
- Apr 25, 2025: FDA document 188080: its numbered observations could not be read reliably from the PDF text.
- Oct 24, 2018: FDA document 113085: its numbered observations could not be read reliably from the PDF text.
State board of pharmacy records
State pharmacy license records for Tennessee are not checked: the Department of Health’s license verification site did not respond to this index’s requests. This index reads only that state’s board actions. Board actions source.
What this covers: Board of Pharmacy actions against pharmacies and other business licensees from the Department of Health’s monthly Disciplinary Action Reports (260 of 263 monthly reports read, 137 with a Board of Pharmacy section). The reports list final board actions for the month named, worded as the department gives them; each action is dated by its report month. Actions against individual pharmacists and technicians are not copied. An entry that gives a city but no state is read as a Tennessee address, as the reports write them. Tennessee pharmacy licenses are not checked. Actions in the data are dated January 2004 to April 2026.
FDA’s 503B list
- Wells Pharmacy, Inc., Dyersburg, TN: last inspection Apr 9, 2026, Form 483 at that inspection: Yes, action FDA lists: Response Letter Issued 10/5/2026; FMD-145 Letter Issued 10/6/2026.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Tennessee Board of Pharmacy disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.